Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155241 | 0.90 | CYP4A11 (0.55) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL2173758 | 0.89 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL2162519 | 0.89 | CYP4A11 (0.72) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL27262281 | 0.89 | MGLL (0.56) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL70185 | 0.88 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL33494 | 0.84 | LOXL2 (0.66) | CYP4A11CYP4F2LOXL2MAPTALDH1A1 | |
| SCHEMBL4050879 | 0.82 | LOXL2 (0.63) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL2655571 | 0.82 | CYP4A11 (0.79) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL1426157 | 0.82 | CYP4A11 (0.68) | CYP4A11CYP4F2LOXL2MAPTCCR6 | |
| SCHEMBL8867548 | 0.82 | CYP4A11 (0.68) | CYP4A11CYP4F2LOXL2MAPTCCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 577 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619922-A | Hydroxamic acid compound, and preparation method and application thereof | 郑州大学 | 2024-09-10 | — | — | CN | claimed |
| CN-116462729-A | Prednisone acetate hapten, artificial antigen and application thereof | 华南农业大学 | 2023-07-21 | — | — | CN | claimed |
| CN-116425759-A | Hapten and artificial antigen for simultaneously detecting various nafil medicines in food and application thereof | 华南农业大学 | 2023-07-14 | — | — | CN | claimed |
| CN-104610166-A | Pyrimidine benzyl hydroxamic acid histone deacetylase inhibitor, and preparation method and application thereof | UNIV SHANDONG | 2015-05-13 | — | — | CN | claimed |
| CN-104530078-A | Thieno [3, 2-d] pyrimidine derivative and preparation method and application thereof | UNIV SHANDONG | 2015-04-22 | — | — | CN | claimed |
| EP-4565565-B1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LTD (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125347-A1 | l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | NXERA PHARMA UK LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-1030755-A | INSECTICIDAL PYRAZOLINES | DU PONT (US) | 1989-02-01 | — | — | CN | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4616086-A | ANTICOAGULANTS | BOEHRINGER MANNHEIM GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | CYP4A11 1125/4885CYP4F2 2916/4885LOXL2 2438/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | CYP4A11 654/4885CYP4F2 1872/4885LOXL2 839/4885 |
| US-12528815-B2 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | ADORA1, ADORA3, OPRL1 | CYP4A11 1791/4885CYP4F2 1930/4885LOXL2 2090/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | CYP4A11 4227/4885CYP4F2 4657/4885LOXL2 2693/4885 |
| US-20260125347-A1 | l,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, OXER1 | CYP4A11 231/4885CYP4F2 601/4885LOXL2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.